- Home
- Products
- Customized ADCs
- CD79b
- Anti-CD79b (clone hu2F2.D7)-BMPEO-DM1 ADC
Anti-CD79b (clone hu2F2.D7)-BMPEO-DM1 ADC (CAT#: ADC-W-170)
This ADC product is comprised of an anti-CD79B monoclonal antibody (clone hu2F2.D7) conjugated via a BMPEO linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- hu2F2.D7
- Name
- CD79B
- Alternative Names
- CD79b molecule, immunoglobulin-associated beta; B29; IGB; AGM6; B-cell antigen receptor complex-associated protein beta chain; Ig-beta; B-cell-specific glycoprotein B29; immunoglobulin-associated B29 protein; CD79b antigen (immunoglobulin-associated beta
- Target Entrez Gene ID
- 974
- Target UniProt ID
- P40259
- Overview
- The B lymphocyte antigen receptor is a multimeric complex that includes the antigen-specific component, surface immunoglobulin (Ig). Surface Ig non-covalently associates with two other proteins, Ig-alpha and Ig-beta, which are necessary for expression and function of the B-cell antigen receptor. This gene encodes the Ig-beta protein of the B-cell antigen component. Alternatively spliced transcript variants encoding different isoforms have been described.
- Overview
- Anti-CD79B antibody, clone # hu2F2.D7
- Clone #
- hu2F2.D7
- Species Reactivity
- Human
- Name
- BMPEO (bis-maleimido-trioxyethylene glycol)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-NCA-90 (Lemalesomab)-MC-MMAF ADC (CAT#: ADC-W-2164)
- Anti-EGFR (Futuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1051)
- Anti-MS4A1 (Tositumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1585)
- Anti-TGFB1 (Metelimumab)-MC-MMAF ADC (CAT#: ADC-W-1804)
- Anti-FOLH1 (MLN591)-VC-MMAE ADC (CAT#: ADC-W-431)
- Anti-CD5 (Telimomab aritox)-SMCC-DM1 ADC (CAT#: ADC-W-932)
- Anti-IL5 (Reslizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1397)
- Anti-TACSTD2 (clone C16)-PEG6-MMAD ADC (CAT#: ADC-W-538)
- Anti-IL9 (Enokizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1449)
- Anti-TFPI (Concizumab)-SPDB-DM4 ADC (CAT#: ADC-W-1791)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-170. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-225 | Anti-CD79b (SN8)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
ADC-W-2554 | Anti-CD79B (Polatuzumab )-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-527 | Anti-CD79B-MCC-DM1 ADC | Mcc (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-237 | Anti-CD79b (clone 10D10)-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-025 | Anti-CD79b (clone huMA79b.v18)-BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-151 | Anti-ERBB2 (clone hu4D5Fabv8)-BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-177 | Anti-CD22 (clone 10F4v3)-BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-028 | Anti-CD79b (clone huMA79b.v28)-BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-153 | Anti-EPHB2 (clone 2H9)-BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
CAT# | Product Name | Linker | Payload |
ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-AA-050 | Protein G-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-487 | Anti-CD70-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-AA-054 | Protein A-MCC-DM1 ADC | MCC (Maleimidomethyl cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-495 | Anti-EGFR (J2898A)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.